Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced that Frank Stonebanks, Renibus’ Co-CEO, and Bhupinder Singh, MD, Renibus’ CMO, will participate in a fireside chat on February 29, 2024, at 3:25 pm ET at the Evercore ISI 2024 Emerging Biotech Conference.
| |
| [22-February-2024] |
| SOUTHLAKE, Texas, Feb. 22, 2024 /PRNewswire/ -- Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced that Frank Stonebanks, Renibus’ Co-CEO, and Bhupinder Singh, MD, Renibus’ CMO, will participate in a fireside chat on February 29, 2024, at 3:25 pm ET at the Evercore ISI 2024 Emerging Biotech Conference, taking place virtually from February 28-29, 2024. Renibus management will also participate in one-on-one meetings with investors during the conference. To view the fireside chat, please visit the events section of the Renibus website at News and Events - Renibus Therapeutics. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients’ lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus’ first-in-a-new-class lead program is RBT-1, which is in a Phase 3 pivotal trial to show a reduction in post-operative complications and improve outcomes following cardiac surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer (Alezuris™) is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile, with a goal of identifying an indication for evaluation in a Phase 2 trial. RBT-3 (iron sucrose), one component of RBT-1, is a novel, low molecular weight iron nanoparticle that has the potential to rapidly restore iron levels and improve blood product utilization in cardiac surgery and/or ER patients. RBT-3 has also demonstrated the potential to mitigate cisplatin induced nephrotoxicity in preclinical models. We are currently exploring opportunities to further the clinical development of RBT-3 in these potential indications. RBT-9 (stannic protoporfin), another component of RBT-1, is a potent anti-inflammatory and antioxidant drug. It has completed Phase 1 (as part of the RBT-1 program) and has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated that RBT-9 has the potential to significantly improve clinical outcomes. Additional work is underway to help inform the future clinical development strategy. RBT-2 (tetrahydrocurcumin) is an oral antioxidant and antifibrotic drug that may have the potential to delay CKD progression. For more information, please visit the Company’s website at www.Renibus.com and engage with us on LinkedIn. Investor and Media Contact: Business Development Contact
SOURCE Renibus Therapeutics |
View original content to download multimedia:
